- NewsCategory：
- All Company news Industry news
common83One result
-
1017
WindMIL Therapeutics ©↔and University of California, Irvine A¥≤↔nnounce Collaboration to Collect Bone Marr→ §ow from Patients with Gliomas
WindMIL Therapeutics and Unive♠©•rsity of California, Irvine Announce Collaboratiβ$on to Collect Bone Marrow from Pat↔∞ients with GliomasWEDNESD∞>★πAY, OCTOBER 16, 2019WindMIL The≥πrapeutics and the Universi♦>ty of California, Irvine (UCI) t€εoday announced that the first pati≤→α ents have been identified in an investigator-®Ω£sponsored study for the collec↔↔tion of bone marrow from patients with gliomas. Tπ he study will evaluate generating ma₹δφφrrow infiltrating lymphocytes (MILs™) for th☆ ★Ωese patients through WindMIL’s proααβ<prietary cellular activation and exp ansion process. The study is being ≥↕¶↕conducted at UCI.“Patients suffering&♠← with glioblastoma a"© ↕re in great need of new, promising treatmen≤☆ ts that might advance the current standard of car₹±♣♣e,” said Daniela A. Bota, MD, PhD, director of t↓✘¥he UCI Health Comprehensiv §↔™e Brain Tumor Program, se ♣ nior associate dean for clinical ↑→research, UCI School of Medicine anεd clinical director, UCI Sue & Bill Gro÷ss Stem Cell Research Center. “The Uλ∏≥niversity of Californ♣§±ia, Irvine is excited to play a key role in r&∞™esearch that may lead to a clinical trial ≈&that enlists the immune sys₽•λ€tem in novel ways to fight this tδ₹®errible disease.”Glio ↔€✘mas are the most common of the malignant brain✘™≥ tumors. Glioblastoma, the mελost common glioma, has a fε↓≤ive-year survival of less than 5 λ₩percent. Additional treatment options '×are urgently needed for these patients.<₹♣ Adoptive immunotherapy ✔is a possible approach for gliomas and th✘β÷e use of MILs, a cell &®♣therapy that is naturally tumor-specific, is Ω↓one such treatment option.Th&✔☆e bone marrow is a unique ni£σ↕che in the immune system to which antigen-expe₹σ"rienced memory T cells t₽↑δraffic and are then maint≠€ained. WindMIL has develop™®←ed a proprietary process to select, ₹®¥§activate and expand these memory ♥÷T cells into MILs. Because mem φεπory T cells in bone "πmarrow occur as a result of ★' the immune system’s recognition of ↑"☆tumor antigens, MILs are s'¥♥★pecifically suited for adopt★αive cellular immunotherapy and ar₩₩e able to directly eradic∑≠ ate or facilitate eradicatio$$n of each patient’s unique cancer. WindMIL i≠<§s currently studying MILs in multiple ↓★∞™myeloma, non-small cel≈λl lung cancer and squamous cell carcinoma of th⧩<e head and neck, and plans t≈↕o expand into other ♦§Ω↑solid tumors.“WindMIL isε≤× looking forward to working with$ the University of California, Irvine on th≥→is exciting project and is op¶εtimistic that MILs may offer the pote∑☆ ntial to help patients with ÷♥¥these hard-to-treat dis★≈"★eases,” said Monil Shah, PharmD, MBA, Chief Devel£♥¥÷opment Officer at WindMIL.informat✔±ion source:pharma focus AsiaThe origi ¥♥nal link:https://www.pharmafocusasia.com/∑₹news/windmil-therapeut•≠ics-and-university-of-california-irvine-announce×★ ≥-collaboration-to-collect-bone-marrow-from-pat÷βients-with-gliomas2019 Asia-p↕•±acific pharma IP Leader¶"★Ω Summit: http://en.zenseegroup.com/p/510934/δ♦will be held in Bei↕♠jing on November 14-15, γ≈✔&and will attract more than 500∑ industry experts from domesti€αc and foreign pharmaceutical companies, biotech≥π÷nology companies, governments, •↑§associations, law firms, intellectual property a★'≈ gents and other companie✘∑™πs to attend.Official regi©₽stration and consultation channels:Contact：AnnPho≠≤≥¥ne: 021-65650305Email：Marketing@zenseegroup.φ≈comhttp://en.zenseegroup.com/p/510934/ -
1016
CRISPR Therapeutics and KSQ Therapeutics Announ Ωce License Agreement to Advance ↔®Companies’ Respective Cell Therapy Programs i•≠n Oncology
CRISPR Therapeutics and KSQ Th≠¥γerapeutics Announce License Agr☆×λ™eement to Advance Companies’ Respectiv✘↑ e Cell Therapy Programs in OncologyWEDNESDAY, OCT↕≈OBER 16, 2019CRISPR Therapeutics, a biopharmaceu✘∑$↓tical company focused on creating transformΩ✔¥ative gene-based medi÷↕£cines for serious diseas©€es, and KSQ Therapeu×®tics, a biotechnology compa₽<✘Ωny using CRISPR technology to enable the compan♦φ₹y’s powerful drug discovery engine to ac<'← hieve higher probabil≤ε∞ities of success in d♣Ωφrug development, today a•♣Ωnnounced a license agreement wher'σ¥eby CRISPR Therapeutics will gain access <£Ω'to KSQ intellectual property (IP) for edi♥÷ting certain novel gene≠® targets in its allogeneic oncology cell therapy☆¥α programs, and KSQ will gain access to CRIS'<&δPR Therapeutics’ IP for editing novel gene tar✘≤ ×gets identified by KSQ as part of its current an ≠d future eTILTM (engin¶★≠eered tumor infiltrating lymp♥₹αhocyte) cell programs."& The financial terms of the a®£<greement are not being disclos♠&→ed.“We are thrilled to gain access to CRISPR Therσ∑apeutics’ foundational IP estate through t¶σhis agreement,” said David Ω&δMeeker, M.D., Chief Executive Of÷↑ficer at KSQ Therapeut↔δics. “Our eTILTM programs involve editing β€∏gene targets in human TILsφ§≥∞ that were discovered at KSQ by applying our pr≤λoprietary CRISPRomics® appr∞✔oach to immune cells in multiple εin vivo models. This agreement clears an∑β important path for us to be able toα♣ bring these programs thro☆£<ugh development and commercialization, le←¥λveraging CRISPR Therapeutics’ proprietary ≈& editing technology.”The gene targets within theΩδ₩ scope of the license agreement were identifieγ✘d using KSQ’s proprietary CRISPRomics® drug disc±↓¶overy engine, which allows gσ←αβenome-scale, in vivo validated, unbia ↔♥sed drug discovery. These specific targ↓₽σets were uncovered in screens to ide§→ntify genetic edits that could enhance the fu<♣∞€nctionality and quality o÷'f adoptive cell thera♠ pies in oncology.“KSQ has built an ↓←πindustry-leading platform to s↓→λcreen for novel gene targets using its tec↔€'hnology, and has identified a g<$roup of targets that could help unloc✔>£≥k the full potential of adoptiv§←σβe cell therapy in oncology,” ≤¶said Samarth Kulkarni, Ph.D., Chief Executive OfΩ₽ficer at CRISPR Thera¶σ♥peutics. “As a result of this licen₩↔→φse agreement, CRISPR Therapeutics will have the☆©λ∞ opportunity to bring these novel♣≈≈< targets into our leading allogeneic CAR-T devel>≥opment platform to further strengthen our fu×"±δture programs in this important therapeutic ar₹α ea.”information source:pha≥∞rma focus AsiaThe original link:ht♦λ× tps:https://www.pharmafocusasia.₩♣®com/news/crispr-therapeutics-∞₩ λand-ksq-therapeutics-announce-license-agreement"≈ ∑-to-advance-companies-respective♦₹-cell-therapy-programs-in-oncology2019 As$>ia-pacific pharma IP Leader Summit: http:♠<>//en.zenseegroup.com/p/510934/ will be held ←€in Beijing on&n>©$bsp;November 14-15, and will attr♦♦≤×act more than 500 industry expert÷"s from domestic and foreign∏→× pharmaceutical companies, biotechnology com$'☆₽panies, governments, associations, law firms, ≥£ ∑intellectual property agents a↔♥•nd other companies to attend.Officγ&ial registration and consultatio∞✔∑↑n channels:Contact：AnnPhone: 021-65650305Email：Mλ↑₩←arketing@zenseegroup.com↔ ♥http://en.zenseegroup.com∞&÷→/p/510934/ -
1015
Shionogi enters into a new licen'"☆≠se agreement and research collaboration for th±♥δe treatment of mycobacterε♠'ial diseases with Hsiri Therapeutics, Inc.σ♣ §
Shionogi enters into $• a new license agree®&×ment and research collaborπβation for the treatment of mycobacterial α↕'αdiseases with Hsiri Therapeutics,φ™→☆ Inc.MONDAY, OCTOBER 14, 2019Shionogi &am≠☆☆p; Co., Ltd. today announced that it has enφ→tered into a new license agre±≠✔≠ement with Hsiri Therapeu∞ε&tics, Inc. (Head Office: Media, PA, USA; Presiden ≤'t and CEO: William Claypool, ≠"∏M.D.; hereafter "Hsiri λ") regarding a collabo♠£≈rative research and development program to dis←&cover and develop additionaσ♥∏l novel therapeutics for non-tuberculous mycobacφ↓αterial (NTM) diseases and tuberculosis (TB). Th↔₽ is new collaboration will include ₽§technology that complements¥ Shionogi's earlier collaboration arrang®£→₩ement with Hsiri.The new technology to be l✘$icensed from Hsiri has a no≠÷vel mechanism of action, will≥≠γ× be complementary to Shionogi's cur ₽rent research with Hsir✔≠÷♥i, and is anticipated to be mo★¥§re effective than current therapie♣±✔s for mycobacterial infections. Shio₽nogi's strength in small<↔∏← molecule drug discovery and development i★β₽n the antibacterial area will supp Ω≤ort development of Hsiri's innovative th♣££§erapeutics in this collaborat¥♣ive program. Under the terms of thi∑♣s agreement, Shionogi will♦♣>Ω have exclusive worldwide rights to develop,£←≠♦ manufacture, and commercialize the coεπ€©mpounds generated from the collaboration. Hsiri✘™ will receive an upfr∑α← ont license fee, potential development ©€milestones, and royalty payments based on ≥↕sales from Shionogi.It is re↔≠π∞ported that the number of pati£≥∏ents suffering from NTM diseases has±₹♦ been increasing, espe↓♠cially in developed count§ ↓ries, in recent years. There is a medical₩↓Ω need to develop novel anti-NTM drug®>s because of the long durati©©on of treatment and insufficient tre•±<™atment outcome of current the&πβ€rapeutics. TB is one of the three major ✔γinfectious diseases in ≤the world, and new cases♥≈β↔ of TB are estimated±← to be 10.4 million/year★♦. Multidrug-resistant TB (MDR-TB) anεγ×<d extensively drug-resistant TB (XDR-TB) have β∑↔$become a major public hea£₹☆lth concern, and novel drugs for MDR-TB and XDR-σ♠γ♥TB are anticipated.Shionogi's research a¥© nd development targets infectio∏±↕us disease as one of its priority a♥₹reas, and Shionogi have positioned "protecting₹•® people from the threat of infec₩≈≥↕tious diseases" as on•₩©>e of its social mission targets. Through thi©<©☆s cooperation, Shionogi strives constan€★©✘tly to bring forth innovative drug ₩≥'s for the treatment of infeδ↑∞ctious diseases, to protect the health of patΩ∑ients we serve.information sourα≠ce:pharma focus AsiaThe o↓α₽riginal link:https:https:https://www.pharmafocε∞γusasia.com/news/shionogi-enters-i≈β≤<nto-a-new-license-agreement-and-rese↓§©arch-collaboration-for-t• he-treatment-of-mycobacteri £©≥al-diseases-with-hsiri-therapeutics-in✘≥φc2019 Asia-pacific pharma I≥ $↕P Leader Summit: http://en.zenseegroup.cΩ>om/p/510934/ will σ♦'≥be held in Beijing o>↕¥n November 14-15, and will att↑→ract more than 500 industry experts↓♠ from domestic and foreiφ♥gn pharmaceutical compani↕™es, biotechnology companies, governments, associ×♣&€ations, law firms, intel☆±lectual property agents and oth♦"er companies to attenΩ≠γ∞d.Official registration and consultation channε≈>els:Contact：AnnPhone: 021-6565♣σ↑0305Email：Marketing@zenseegroup.comhttp:₩←←//en.zenseegroup.com/p/510934/ -
1014
Advaxis and UCLA Enter Col≥αlaboration for Glioblas↓♠®>toma Immunotherapy Discovery Research
Advaxis and UCLA Enter ∑§ ₩Collaboration for Gl☆↓↑•ioblastoma Immunotherapy Discovery ResearchFπ↕RIDAY, OCTOBER 11, 2019Advaxis, Inc., ×±a clinical-stage biotech≥÷nology company focused on the ↔↕₩₽discovery, development and commercial$α★®ization of immunotherapy pr ∏oducts, today announced a research collα∑★γaboration agreement with the Universi™<ty of California Los Angeles (←β♦UCLA) to conduct preclinical studies ↔✘evaluating the Company’s Lm technol≥ ogy in mouse tumor mo≠₩dels of glioblastoma multiforme (GBM). Specifi₹± cally, the collaboration with Dr. Vaithi Arum¥±♣ugaswami’s group at UCLA’s Departmen£∑t of Molecular and Medical Phar☆macology will investigate anti-tumor i€"∑mmunity and anti-tumor responses generat₹ed by Lm vaccines that express div↑ erse glioblastoma neoantigens.“W↓☆₩e are excited that Dr. Arumugaswami and hi↓¶s colleagues at UCLA will investigate the potential of our Lm technolog¶¶™♥y platform in GBM, one of the deadliest cancer∑≈π§s,” said Andres Gutierrez, Executive ©♣Vice President and Chief Medical ¥'♣<Officer of Advaxis. “Contrary to other tu≥∞mor types, GBM has not seen much su¶♥ccess in targeting by immunothera₽↕©peutic agents due to a low tu↔₹≈mor mutation burden, high tumor heterogeneityφε and presence of the blood brain barrier, amoΩ∞ng other factors. Hence, D ☆•r. Arumugaswami’s ch×&←aracterization of the neoantigen→₩≥ landscape and immune response§¥s to Lm- constructs may lead to the ↑" ♥development of novel therapies with c♥✔linical activity in this elusiv₽↓≤♣e cancer.”information sou" rce:pharma focus AsiaThe or↑$iginal link:https:https:https://www.pharmaf&✔ocusasia.com/news/advaxis-and-ucla≠←↕-enter-collaboration-for-glioblastoma-immun∑∑otherapy-discovery-research2019 Asia-♣∏☆↕pacific pharma IP Leader Summit: http★♦β://en.zenseegroup.com/p ©®/510934/will be held in Beijing &nbs≤¥p;on November 14-15, and&♥ will attract more than 500 industry expe÷₩εrts from domestic and foreign pharmaceutical comp¥♠₹anies, biotechnology companies, government©↓s, associations, law firms, i'↕✘ntellectual property agentsδ> and other companies to atten≈λ↕d.Official registration and consultation ch €annels:Contact：AnnPhone: 021-65650305Email：Marke✔$ •ting@zenseegroup.comhttp://en.zenseegroup.com£₹•>/p/510934/ -
1011
Viela Bio Enters Strategic ¶↑₹Collaboration with Mitsubishi Tanabe Pharm♣∏§♦a to Develop and Commerciali♠∞ze Inebilizumab for Autoimmune Diseases in₽₹ Japan and Other Asia R&§✘φegions
THURSDAY, OCTOBER 10, 2019Viela Bio, Inc. and ∏♦✔→Mitsubishi Tanabe Pharma Corporati☆↑☆on (“MTPC”) today announced a collabor ★βation focused on the ∑αdevelopment and commercializatio±★<₩n of inebilizumab – Viela’s humanized anti-CD1δ<₹9 monoclonal antibody – in nine Asia regionφσ₹s for neuromyelitis optica spectrum d₹λisorder (NMOSD), as well as other poten★πtial future indications.“This partn•φ✔ership adds to our ability toβ commercialize inebilizumab >§©globally, subject to regulatory approval,” co←©mmented Bing Yao, Ph.D.,∞σ∞ Viela’s Executive Chairman an≤®λd Chief Executive Officer. “As a well-estab>₹☆↑lished pharmaceutical company i "∏n Japan, Mitsubishi Tanabe has st↔≥™£rong product development and commercializat≤₽ion capabilities in Asia,∑✔ and we believe, is an idealα☆ partner for expanding inebilizumab’s potent¥•ial reach to thousands of additional patients i ®®n need of viable treatments, with N$♥≥≈MOSD as an initial indication.”Under term✘₽♦s of the collaboration, Viela will recei←£ve an up-front licensing fee of $30 mi≠≈↑llion as well as additional pay→₩αments contingent on certain↑γ development and comm ↓γπercial milestones, plus↔' payments based, in part,£±≤ on sales revenue. MTPC will be responsible f'∏♠or leading development and coδ←≠™mmercialization of in∏σ±ebilizumab in Japan, ≈Thailand, South Korea, Indonesia, Vietnam,∞π Malaysia, Philippines, Sin♠₩€gapore, and Taiwan.“ ©Our organization is delighted to par¶αtner with Viela to develop and commercia ¶↓lize their promising prodδ₽→uct candidate inebilizumab for autoimmune anγ∑ d inflammatory disea→≥ses,” said Masayuki Mitsuka, MTPC President☆♠¥ & Representative Director. “Iπ←nebilizumab is an exc©γ£δiting product candid©✔♠ate that, based on thλ®←←e results from the N-MOmentum piv&'×±otal study, is well-positioned to provi♦≠ σde meaningful benefit for patie≠♠σ∑nts with NMOSD, and p& ÷ otentially additional diseases, subject γ∏to regulatory approval. We are excited to™φγ↔ work with Viela to π≤advance inebilizumab in Japan and oth÷π£er Asia regions, and look f≥α•×orward to a productive " partnership between our companies.”The U.S. F $πood and Drug Administration (FDA↕" ) recently accepted for ₽'βreview Viela’s Biologics License Applica§$tion (BLA) for inebilizumab for the treatment of φ NMOSD. information sour∞ce:pharma focus AsiaTheΩ☆λ original link:https:https://www.pharmafocusaλ&sia.com/news/viela-b¶↔io-enters-strategic-collaboratio ☆¥n-with-mitsubishi-tanabe-pharma-t≤♣αo-develop-and-commercializ↓₹₩e-inebilizumab-for-auto™™immune-diseases-in-japan-and-other-asia-regions±↑2019 Asia-pacific pharma I✘§§P Leader Summit: http://en&φ∏→.zenseegroup.com/p/510934/wi↕$ll be held in Be↕¶↕₽ijing on ₹✘↑σNovember 14-15, and ≠"♣will attract more than 500 industr £→¶y experts from domestic and foreign pharmace₩£πutical companies, biotechnology companies, φ←σgovernments, associati✔®ons, law firms, intellectual property agen<★ts and other companies to attend.Of≤₹ficial registration and consultation channel¥≥↔s:Contact：AnnPhone: 021-65650305Email：Marke÷♠±ting@zenseegroup.comhttp://en.zenseegro↔>₩up.com/p/510934/
Contact Us
Zensee_Daystar online
© 2011-2016